Previous research has shown an increase in hypothalamo-pituitary-adrenal axis activity following naloxone administration to morphine-dependent rats. In the present study, we investigated the adaptive changes in the noradrenaline (NA) and dopamine (DA) systems in the hypothalamic paraventricular nucleus (PVN) during morphine dependence and withdrawal. Additionally, we examined the possible change in 3′,5′-cyclic adenosine monophosphate (cAMP) levels in that nucleus under the same conditions. Rats were made dependent on morphine by morphine or placebo (naïve) pellet implantation for 7 days. On day 8, rat groups received an acute injection of saline or naloxone (1 mg/kg subcutaneously) and were decapitated 30 min later. NA and DA content as well as their metabolite production in the PVN were estimated by HPLC/ED. Both plasma corticosterone levels and cAMP concentration in the PVN were measured by RIA. Naloxone administration to morphine-dependent rats (withdrawal) induced a pronounced increase in the production of both the NA metabolite MHPG and the DA metabolite DOPAC and an enhanced NA and DA turnover. Furthermore, an increase in corticosterone secretion was observed in parallel to the changes in catecholamine turnover. However, no alterations in cAMP levels were seen during morphine withdrawal. These results raise the possibility that catecholaminergic afferents to the PVN could play a significant role in the alterations of PVN functions and consequently in the pituitary-adrenal response during morphine abstinence syndrome. These data provide further support for the idea of adaptive changes in catecholaminergic neurons projecting to the PVN during chronic morphine exposure.

Keywords:
Paraventricular nucleus, Catecholamines, cAMP, Naloxone, Morphine behaviour, Adrenal steroids, Withdrawal syndrome
1.
Nestler EJ: Molecular mechanism of drug addiction. J Neurosci 1992;12:2439–2450.
2.
Nestler EJ, Hope BT, Widnell KL: Drug addiction: A model for molecular basis of neural plasticity. Neuron 1993;11:995–1006.
3.
Koob GF: Drugs of abuse: Anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992;13:177–184.
4.
Self DW, Nestler EJ: Molecular mechanisms of drug reinforcement and addiction. Annu Rev Neurosci 1995;18:463–495.
5.
Guitart X, Thompson MA, Mirante CK, Greenberg ME, Nestler EJ: Regulation of cyclic AMP response element-binding protein (CREB) phosphorylation by acute and chronic morphine in the tar locus coeruleus. J Neurochem 1992;58:1168–1171.
6.
Pechnick RN: Effects of opioids on the hypothalamo-pituitary-adrenal axis. Annu Rev Pharmacol Toxicol 1993;32:353–382.
7.
Alcaraz C, Vargas ML, Fuente T, Milanés MV: Chronic naloxone treatment induced supersensitivity to a μ but not to a κ agonist at the hypothalamus-pituitary-adrenocortical axis level. J Pharmacol Exp Ther 1993;266:1602–1606.
8.
Gonzálvez ML, Milanés MV, Vargas ML: Effects of acute and chronic administration of μ- and δ-opioid agonists on the hypothalamic-pituitary-adrenocortical (HPA) axis in the rat. Eur J Pharmacol 1991;200:155–158.
9.
Martínez JA, Vargas ML, Fuente T, del Río-García J, Milanés MV: Plasma β-endorphin and cortisol levels in morphine-tolerant rats and in naloxone-induced withdrawal. Eur J Pharmacol 1990;182:117–123.
10.
Vargas ML, Martínez-Piñero MG, Milanés MV: Neurochemical activity of noradrenergic neurons and pituitary-adrenal response after naloxone-induced withdrawal: The role of calcium channels. Naunyn-Schmiedeberg’s Arch Pharmacol 1997;355:501–506.
11.
Suemaru S, Dallman MF, Darlington DN, Cascio CS, Shisako J: Role of α-adrenergic mechanisms in effects of morphine on the hypothalamo-pituitary-adrenocortical and cardiovascular systems in the rat. Neuroendocrinology 1989;49:181–190.
12.
Martínez-Piñero MG, Milanés MV, Alcaraz C, Vargas ML: Catecholaminergic mediation of morphine-induced activation of pituitary-adrenocortical axis in the rat: Implication of α- and β-adrenoceptors. Brain Res 1994;668:122–128.
13.
Milanés MV, Laorden ML, Chapleur-Chateau M, Burlet A: Alterations in corticotropin-releasing factor and vasopressin content in rat brain during morphine withdrawal. Correlation with hypothalamic noradrenergic activity and pituitary-adrenal response. J Pharmacol Exp Ther 1998;285:700–706.
14.
Milanés MV, Laorden ML, Chapleur-Chateau M, Burlet A: Differential regulation of corticotropin-releasing factor and vasopressin in discrete brain regions after morphine administration: Correlations with hypothalamic noradrenergic activity and pituitary-adrenal response. Naunyn-Schmiedeberg’s Arch Pharmacol 1997;356:603–610.
15.
Palkovits M: Anatomy of neural pathways affecting CRH secretion. Ann NY Acad Sci 1987;512:139–148.
16.
Cunningham ET, Sawchenko PE: Anatomical specificity of noradrenergic inputs to the paraventricular and supraoptic nuclei of the rat hypothalamus. J Comp Neurol 1988;274:60–76.
17.
Owens MJ, Nemeroff CB: Physiology and pharmacology of corticotropin releasing factor. Pharmacol Rev 1991;43:425–473.
18.
Plotsky PM, Cunningham ET, Widmaier EP: Catecholaminergic modulation of corticotropin-releasing factor and adrenocorticotropin secretion. Endocr Rev 1989;10:437–458.
19.
Itoi K, Suda T, Tozawa F, Dobashi I, Ohmori N, Sakai Y, Abe K, Demura H: Microinjection of norepinephrine into the paraventricular nucleus of the hypothalamus stimulates corticotropin-releasing factor gene expression in conscious rats. Endocrinology 1994;135:2177–2182.
20.
Bugajski J, Gadek-Michalska A, Olowska A, Borycz J, Glód R, Bugajski AJ: Adrenergic regulation of the hypothalamic-pituitary-adrenal axis under basal and social stress conditions. J Physiol Pharmacol 1995;46:297–312.
21.
Everitt BJ, Meister B, Hökfelt T: The organization of monoaminergic neurons in the hypothalamus in relation to neuroendocrine integration; in Nemeroff CB (ed): Neuroendocrinology. Boca Raton, CRC Press, 1992, pp 87–127.
22.
Torres G, Horowitz JM: Individual and combined effects of ethanol and cocaine on intracellular signals and gene expression. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:561–596.
23.
Gonzálvez ML, Milanés MV, Martínez-Piñero MG, Marín MT, Vargas ML: Effects of intracerebroventricular clonidine on the hypothalamic noradrenaline and plasma corticosterone levels of opiate naïve rats and after naloxone-induced withdrawal. Brain Res 1994;647:199–203.
24.
Couceyro P, Douglass J: Precipitated morphine withdrawal stimulates multiple activator protein-1 signaling pathways in rat brain. Mol Pharmacol 1995;47:29–39.
25.
Berhow MT, Russel DS, Terwilliger RZ, Beitner-Johnson D, Self DW, Lindsay RM, Nestler EJ: Influence of neurotrophic factors on morphine- and cocaine-induced biochemical changes in the mesolimbic dopamine system. Neuroscience 1995;68:969–979.
26.
Yokoe T, Audhya T, Brown C, Hutchinson B, Passarelli J, Hollander CS: Corticotropin-releasing factor levels in the peripheral plasma and hypothalamus of the rat vary in parallel with changes in the pituitary-adrenal axis. Endocrinology 1988;123:1348–1354.
27.
Palkovits M: Isolated removal of hypothalamic or other brain nuclei of the rat. Brain Res 1973;59:449–450.
28.
Palkovits M, Brownstein MJ: Maps and guide to microdissection of the rat brain. New York, Elsevier, 1988.
29.
Artigas F, Sarrias MJ, Adell A, Gelpí E: Quantitation of total MHPG in the rat brain using a nonenzymatic hydrolysis procedure. Effects of drugs. Life Sci 1986;39:1571–1578.
30.
Lookingland KJ, Ireland LM, Gunnet JW, Manzanares J, Tian Y, Moore KE: 3-Methoxy-4-hydroxyphenylethyleneglycol concentrations in discrete hypothalamic nuclei reflect the activity of noradrenergic neurons. Brain Res 1991;559:82–88.
31.
Ignar DM, Kuhn CM: Effects of specific μ and κ opiate tolerance and abstinence on hypothalamo-pituitary-adrenal axis secretion in the rat. J Pharmacol Exp Ther 1990;255:1287–1295.
32.
De Vries TJ, Tjon Tien Ril GHK, van der Laan JW, Mulder AH, Schoffelmeer ANM: Chronic exposure to morphine and naltrexone induces changes in catecholaminergic neurotransmission in rat brain without altering μ-opioid receptor sensitivity. Life Sci 1993;52:1685–1693.
33.
Manzanares J, Lookingland KJ, Moore KE: κ-opioid receptor-mediated regulation of α-melanocyte stimulating hormone secretion and tuberohypophysial dopaminergic neuronal activity. Neuroendocrinology 1990;52:200–205.
34.
Lightman SL, Young WS: Corticotropin-releasing factor, vasopressin and pro-opiomelanocortin mRNA responses to stress and opiates in the rat. J Physiol 1988;403:511–523.
35.
Harbuz M, Russell JA, Sumner BEH, Kawata M, Lightman SL: Rapid changes in the content of proenkephalin A and corticotrophin releasing hormone mRNAs in the paraventricular nucleus during morphine withdrawal in urethane-anesthetized rats. Mol Brain Res 1991;9:285–291.
36.
Petrusz P, Merchenthaler I: The corticotropin-releasing factor system; in Nemeroff CB (ed): Neuroendocrinology. Boca Raton, CRC Press, 1992, pp 129–183.
37.
Hasting JA, Pavia JM, Morris MJ: Altered in vivo catecholamine release in the hypothalamic paraventricular nucleus of the aged rat. Naunyn-Schmiedeberg’s Arch Pharmacol 1996;353:161–167.
38.
Borowsky B, Kuhn CM: GBR12909 stimulates hypothalamo-pituitary-adrenal activity by inhibition of uptake at hypothalamic dopaminergic neurons. Brain Res 1993;613:251–258.
39.
Torres G, Horowitz JM, Lee S, Rivier C: Cocaethylene stimulates the secretion of ACTH and corticosterone and the transcriptional activation of hypothalamic NGFI-B. Mol Brain Res 1996;43:225–232.
40.
Valverde O, Tzavara E, Hanoune J, Roques BP, Maldonado R: Protein kinases in the rat nucleus accumbens are involved in the aversive component of opiate withdrawal. Eur J Neurosci 1997;8:2671–2678.
41.
Sheu MJ, Sribanditmongkol P, Santosa DN, Tejwani GA: Inhibition of morphine tolerance and dependence by diazepam and its relation to cyclic AMP levels in discrete rat brain regions and spinal cord. Brain Res 1995;675:31–37.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.